Show simple item record

dc.contributor.authorHermida-Prieto, Manuel
dc.contributor.authorGarcia-Castro, Javier 
dc.contributor.authorMariñas-Pardo, Luis
dc.date.accessioned2022-04-20T09:26:41Z
dc.date.available2022-04-20T09:26:41Z
dc.date.issued2021-12-20
dc.identifier.citationJ Clin Med. 2021;10(24):5981.es_ES
dc.identifier.issn2077-0383es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14123
dc.description.abstractKeratoconjunctivitis sicca (KCS) is characterized by ocular discomfort, conjunctival hyperaemia, and corneal scarring, causing reduced aqueous tear production that can be measured using the standard Schirmer tear test (STT). Canine adipose tissue-derived MSCs (cATMSCs) have been proposed as treatment due to their anti-inflammatory effect, by releasing cytokines and immunomodulatory soluble factors. The aim of this study was to evaluate the effect of the systemic administration of cATMSCs on tear production in dogs with immune-mediated KCS, compared to classical Cyclosporine A (CsA) treatment. Twenty-eight client-owned dogs with spontaneous KCS were allocated in the experimental group (n = 14, treated with systemic cATMSCs or control group (n = 14, treated with CsA). SST values increased significantly at days 15 (p = 0.002), 45 (p = 0.042) and 180 (p = 0.005) with no observed side-effects in the experimental group. Eyes with an initial STT value of 11-14 mm/min maintained significant improvement at day 180, needing only artificial tears as treatment. Eyes with an initial STT value <11 mm/min needed cyclosporin treatment at day 45, so follow-up was stopped. Control animals treated with CsA did not improve their STT at day 180. Systemic allogeneic cATMSCs application appeared to be a feasible and effective therapy with positive outcome in dogs with initial STT between 11-14 mm/min, with a significant improvement in tear production. The STT increment was maintained for at least 180 days, without needing additional medication, thus suggesting it could constitute an alternative therapy to classical immunosuppressive treatments.es_ES
dc.description.sponsorshipThis work was supported by the Madrid Regional Government (Avancell-CM; S2017/BMD-3692) and Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS-ISCIII; RD21/0017/0005) to J.G.-C.es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectSchirmer tear testes_ES
dc.subjectKeratoconjunctivitis siccaes_ES
dc.subjectMesenchymal stem cellses_ES
dc.titleSystemic Treatment of Immune-Mediated Keratoconjunctivitis Sicca with Allogeneic Stem Cells Improves the Schirmer Tear Test Score in a Canine Spontaneous Model of Diseasees_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID34945277es_ES
dc.format.volume10es_ES
dc.format.number24es_ES
dc.format.page5981es_ES
dc.identifier.doi10.3390/jcm10245981es_ES
dc.contributor.funderComunidad de Madrid (España) es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/jcm10245981es_ES
dc.identifier.journalJournal of Clinical Medicinees_ES
dc.repisalud.centroISCIII::Instituto de Investigación de Enfermedades Rarases_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD21/0017/0005


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional